Medical Training AICellular Senescence and Senolytics
Evaluate senescent cell biology and senolytic strategies well enough to counsel patients and weigh protocols critically.
What this track covers
This track covers the biology of cellular senescence and the SASP, the pharmacology of senolytic and senomorphic compounds under investigation, and the safety and patient-selection questions clinicians raise before considering these approaches. It is oriented toward building a working framework for evaluating evidence and discussing risks, not toward a fixed treatment protocol.
What you will practice
- Distinguish senescent cell markers and SASP factors from normal aging changes
- Compare mechanisms of action across proposed senolytic and senomorphic agents
- Identify contraindications and drug interaction concerns before considering a senolytic approach
- Apply a structured framework for screening patients who ask about senolytics
- Recognize which senescence-driven conditions have supporting evidence versus extrapolated claims
Simulator scenario
A virtual patient with osteoarthritis and frailty asks about senolytics after reading about them online, requiring the clinician to counsel on evidence quality and safety before addressing eligibility.
Board question topics
- Cell cycle arrest and senescence markers
- Mechanisms of senolytic versus senomorphic agents
- Drug interaction and contraindication screening
- Evidence base for senescence-driven conditions
Ask the tutor
The tutor only answers from licensed sources (FDA prescribing information, public guidelines and our own material) and says when it has none. Educational use only, never patient-specific advice.
Free during the beta. Sign in with your email, no password.
Start free